Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2024
0mins
Should l Buy ?
Source: PRnewswire
- Calliditas Therapeutics Announcements: Calliditas presented an efficacy analysis of Nefecon and sparsentan at ERA 2024, showing benefits of Nefecon in IgA nephropathy treatment.
- Real-World Analysis of Systemic Glucocorticoids: A study highlighted significant side effects and costs for IgAN patients treated with systemic glucocorticoids like Prednisone.
- Matching-Adjusted Indirect Comparison Study: The study compared Nefecon and sparsentan's effects on kidney function deterioration in IgAN patients, favoring Nefecon.
- TARPEYO Indication and Safety Information: TARPEYO is indicated to reduce kidney function loss in IgAN adults, with important safety information provided.
- About IgA Nephropathy: IgA nephropathy is a rare autoimmune disease affecting the kidneys due to the deposition of immune complexes, potentially leading to end-stage renal disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
